Merck Frosst Canada Ltd. Release: RotaTeq(TM) Is Approved In Canada - The First And Only Vaccine In Canada To Prevent Rotavirus Gastroenteritis In Infants

Published: Aug 23, 2006

Parents will now be able to protect their infants against a potentially severe virus as Merck Frosst Canada Ltd. announced that Health Canada has approved RotaTeq(TM), the first and only vaccine available in Canada for use in preventing rotavirus gastroenteritis (serotypes G1, G2, G3, G4 and P1(8)) in infants. RotaTeq(TM) is an oral, three dose vaccine given to infants between the ages of six to 32 weeks.

Back to news